Life sciences company Neogen (NASDAQ: NEOG) will be reporting results this Thursday morning. Here’s what you need to know.

Neogen beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $225.5 million, down 4.8% year on year. It was a strong quarter for the company, with full-year revenue guidance exceeding analysts’ expectations and full-year EBITDA guidance topping analysts’ expectations.

Is Neogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Neogen’s revenue to decline 6% year on year to $203.9 million, in line with the 5.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.04 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Neogen has missed Wall Street’s revenue estimates five times over the last two years.

With Neogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare equipment and supplies stocks. However, investors in the segment have had steady hands going into earnings, with share prices up 1.3% on average over the last month. Neogen’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $7.67 (compared to the current share price of $5.61).

P.S. While everyone's chasing Nvidia, we found a hidden AI semiconductor winner trading at a fraction of the price. See our #1 pick before Wall Street catches on.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.